These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2831046)

  • 1. Comparative activity of LY146032 against anaerobic cocci.
    Greenwood D; Palfreyman J
    Eur J Clin Microbiol; 1987 Dec; 6(6):682-4. PubMed ID: 2831046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
    Chisari G
    Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci.
    Andrew JH; Wale MC; Wale LJ; Greenwood D
    J Antimicrob Chemother; 1987 Aug; 20(2):213-21. PubMed ID: 2822649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria].
    Caillon J; Juvin ME; Pirault JL; Drugeon HB
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):540-8. PubMed ID: 2552378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.
    Niu WW; Neu HC
    Antimicrob Agents Chemother; 1991 May; 35(5):998-1000. PubMed ID: 1649577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.
    Appelbaum PC; Spangler SK; Crotty E; Jacobs MR
    J Antimicrob Chemother; 1989 Apr; 23(4):509-16. PubMed ID: 2545656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of the new peptolide antibiotic LY146032 against staphylococci.
    Peters G; Schumacher-Perdreau F; Pulverer G
    Eur J Clin Microbiol; 1987 Dec; 6(6):685. PubMed ID: 2831047
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of LY146032 against gram-positive bacteria.
    Silva M; Jacobus NV; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):79-85. PubMed ID: 2838217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of LY 333328 against anaerobic gram-positive bacteria.
    Sillerström E; Wahlund E; Nord CE
    J Chemother; 1999 Apr; 11(2):90-2. PubMed ID: 10326737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F; Neu HC
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of the new cyclic lipopeptide LY146032 against Corynebacterium species.
    Spitzer PG; Eliopoulos GM; Karchmer AW; Moellering RC
    Eur J Clin Microbiol; 1987 Apr; 6(2):183-5. PubMed ID: 3036499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria.
    Hassan H; O'Hare MD; Felmingham D
    Singapore Med J; 1990 Feb; 31(1):56-8. PubMed ID: 2139737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of the new glycopeptide decaplanin.
    Neu HC; Chin NX; Niu WW
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.